Neusentis is categorized under Commercial Medical Research in Durham, NC and active since 1992.
Neusentis was established in 1992, and today employs 1 to 4, earning Unknown per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 5417112 by the NAICS.
If you are seeking more information, feel free to contact P Kay Wagoner, Chief Executive Officer at the company’s single location by writing to 4222 Emperor Boulevard # 350, Durham, North Carolina NC 27703 or by phoning (919) 941-5206. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Neusentis |
| Contact Person: | P Kay Wagoner, Chief Executive Officer |
| Address: | 4222 Emperor Boulevard # 350, Durham, North Carolina 27703 |
| Phone Number: | (919) 941-5206 |
| Website Address: | neusentis.com |
| Annual Revenue (USD): | Unknown |
| Founded: | 1992 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 5417112 |
| Share This Business: |
Neusentis was started in 1992 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 5417112. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact P Kay Wagoner, Chief Executive Officer for inquiries that concern Neusentis by calling the company number (919) 941-5206, as your correspondence is most welcome. Additionally, the physical location of the single location of Neusentis can be found at the coordinates 35.87328,-78.84678 as well as the street address 4222 Emperor Boulevard # 350 in Durham, North Carolina 27703.
For its online presence, you may visit Neusentis’s website at neusentis.com and engage with its social media outlets through on Twitter and on Facebook.